Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI

Enferm Infecc Microbiol Clin (Engl Ed). 2019 Oct;37(8):535-541. doi: 10.1016/j.eimc.2018.03.018. Epub 2018 Jun 28.
[Article in English, Spanish]


Aspergillus infection is a significant cause of morbi-mortality in an at-risk population. The Study Group of Fungal Infections (GEMICOMED) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) has reviewed announcements made in invasive aspergillosis management. We have organized our recommendations in such a way as to provide a guide in resolving different clinical situations concerning the entire spectrum of invasive diseases caused by Aspergillus in various populations. Diagnostic approach, treatment and preventions strategies are outlined. It is not our aim that these guidelines supplant clinical judgment with respect to specific patients; however, it is our objective to perform a comprehensive summary of quality of care evidence for invasive aspergillosis management in different settings.

Keywords: Aspergillosis; Aspergilosis; Isavuconazol; Isavuconazole; Manejo clínico; Monitorización de noveles; Therapeutic drug monitoring; Tratamiento; Treatment; Voriconazol; Voriconazole.

Publication types

  • Practice Guideline

MeSH terms

  • Aspergillosis / diagnosis*
  • Aspergillosis / drug therapy*
  • Humans
  • Invasive Fungal Infections / diagnosis*
  • Invasive Fungal Infections / drug therapy*